Literature DB >> 33524936

Host transcriptional response to TB preventive therapy differentiates two sub-groups of IGRA-positive individuals.

Claire Broderick1, Jacqueline M Cliff2, Ji-Sook Lee2, Myrsini Kaforou3, David Aj Moore4.   

Abstract

We hypothesised that individuals with immunological sensitisation to Mycobacterium tuberculosis (Mtb), conventionally regarded as evidence of latent tuberculosis infection (LTBI), would demonstrate binary responses to preventive therapy (PT), reflecting the differential immunological consequences of the sterilisation of viable infection in those with active Mtb infection versus no Mtb killing in those who did not harbour viable bacilli. We investigated longitudinal whole blood transcriptional profile responses to PT of Interferon gamma release assay (IGRA)-positive tuberculosis contacts and IGRA-negative, tuberculosis-unexposed controls. Longitudinal unsupervised clustering analysis with a subset of 474 most variable genes in antigen-stimulated blood separated the IGRA-positive participants into two distinct subgroups, one of which clustered with the IGRA-negative controls. 117 probes were differentially expressed over time between the two cluster groups, many of them associated with immunological pathways important in mycobacterial control. We contend that the differential host RNA response reflects lack of Mtb viability in the group that clustered with the IGRA-negative unexposed controls, and Mtb viability in the group (1/3 of IGRA-positives) that clustered away. Gene expression patterns in the blood of IGRA-positive individuals emerging during the course of PT, which reflect Mtb viability, could have major implications in the identification of risk of progression, treatment stratification and biomarker development.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Latent tuberculosis infection; Preventive therapy; Transcriptome

Mesh:

Substances:

Year:  2020        PMID: 33524936      PMCID: PMC7985621          DOI: 10.1016/j.tube.2020.102033

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  31 in total

1.  Adjusting batch effects in microarray expression data using empirical Bayes methods.

Authors:  W Evan Johnson; Cheng Li; Ariel Rabinovic
Journal:  Biostatistics       Date:  2006-04-21       Impact factor: 5.899

2.  A Dirichlet process mixture model for clustering longitudinal gene expression data.

Authors:  Jiehuan Sun; Jose D Herazo-Maya; Naftali Kaminski; Hongyu Zhao; Joshua L Warren
Journal:  Stat Med       Date:  2017-06-15       Impact factor: 2.373

3.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.

Authors:  C C Whalen; J L Johnson; A Okwera; D L Hom; R Huebner; P Mugyenyi; R D Mugerwa; J J Ellner
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

4.  Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Authors:  Dereck R Tait; Mark Hatherill; Olivier Van Der Meeren; Ann M Ginsberg; Elana Van Brakel; Bruno Salaun; Thomas J Scriba; Elaine J Akite; Helen M Ayles; Anne Bollaerts; Marie-Ange Demoitié; Andreas Diacon; Thomas G Evans; Paul Gillard; Elizabeth Hellström; James C Innes; Maria Lempicki; Mookho Malahleha; Neil Martinson; Doris Mesia Vela; Monde Muyoyeta; Videlis Nduba; Thierry G Pascal; Michele Tameris; Friedrich Thienemann; Robert J Wilkinson; François Roman
Journal:  N Engl J Med       Date:  2019-10-29       Impact factor: 91.245

5.  Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics.

Authors:  Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

6.  Revisiting the timetable of tuberculosis.

Authors:  Marcel A Behr; Paul H Edelstein; Lalita Ramakrishnan
Journal:  BMJ       Date:  2018-08-23

7.  Is Mycobacterium tuberculosis infection life long?

Authors:  Marcel A Behr; Paul H Edelstein; Lalita Ramakrishnan
Journal:  BMJ       Date:  2019-10-24

8.  The reactome pathway knowledgebase.

Authors:  Bijay Jassal; Lisa Matthews; Guilherme Viteri; Chuqiao Gong; Pascual Lorente; Antonio Fabregat; Konstantinos Sidiropoulos; Justin Cook; Marc Gillespie; Robin Haw; Fred Loney; Bruce May; Marija Milacic; Karen Rothfels; Cristoffer Sevilla; Veronica Shamovsky; Solomon Shorser; Thawfeek Varusai; Joel Weiser; Guanming Wu; Lincoln Stein; Henning Hermjakob; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

9.  Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers.

Authors:  Chloe I Bloom; Christine M Graham; Matthew P R Berry; Fotini Rozakeas; Paul S Redford; Yuanyuan Wang; Zhaohui Xu; Katalin A Wilkinson; Robert J Wilkinson; Yvonne Kendrick; Gilles Devouassoux; Tristan Ferry; Makoto Miyara; Diane Bouvry; Dominique Valeyre; Valeyre Dominique; Guy Gorochov; Derek Blankenship; Mitra Saadatian; Phillip Vanhems; Huw Beynon; Rama Vancheeswaran; Melissa Wickremasinghe; Damien Chaussabel; Jacques Banchereau; Virginia Pascual; Ling-Pei Ho; Marc Lipman; Anne O'Garra
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study.

Authors:  Myrsini Kaforou; Victoria J Wright; Tolu Oni; Neil French; Suzanne T Anderson; Nonzwakazi Bangani; Claire M Banwell; Andrew J Brent; Amelia C Crampin; Hazel M Dockrell; Brian Eley; Robert S Heyderman; Martin L Hibberd; Florian Kern; Paul R Langford; Ling Ling; Marc Mendelson; Tom H Ottenhoff; Femia Zgambo; Robert J Wilkinson; Lachlan J Coin; Michael Levin
Journal:  PLoS Med       Date:  2013-10-22       Impact factor: 11.069

View more
  4 in total

1.  Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.

Authors:  Julie G Burel; Akul Singhania; Paige Dubelko; Julius Muller; Rachel Tanner; Eneida Parizotto; Martin Dedicoat; Thomas E Fletcher; James Dunbar; Adam F Cunningham; Cecilia S Lindestam Arlehamn; Donald G Catanzaro; Antonino Catanzaro; Timothy Rodwell; Helen McShane; Matthew K O'Shea; Bjoern Peters
Journal:  Tuberculosis (Edinb)       Date:  2021-09-14       Impact factor: 3.131

Review 2.  Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.

Authors:  Laura Olbrich; Lisa Stockdale; Robindra Basu Roy; Rinn Song; Luka Cicin-Sain; Elizabeth Whittaker; Andrew J Prendergast; Helen Fletcher; James A Seddon
Journal:  PLoS Pathog       Date:  2021-12-09       Impact factor: 6.823

Review 3.  Transcriptomics for child and adolescent tuberculosis.

Authors:  Myrsini Kaforou; Claire Broderick; Ortensia Vito; Michael Levin; Thomas J Scriba; James A Seddon
Journal:  Immunol Rev       Date:  2022-07-12       Impact factor: 10.983

4.  The Variation of Transcriptomic Perturbations is Associated with the Development and Progression of Various Diseases.

Authors:  Zehua Dong; Qiyu Yan; Xiaosheng Wang
Journal:  Dis Markers       Date:  2022-09-26       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.